BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32024543)

  • 1. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
    Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
    J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer.
    Zhang YZ; Lai HL; Huang C; Jiang ZB; Yan HX; Wang XR; Xie C; Huang JM; Ren WK; Li JX; Zhai ZR; Yao XJ; Wu QB; Leung EL
    Phytomedicine; 2024 Jun; 128():155431. PubMed ID: 38537440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer.
    Pan X; Zhang W; Wang L; Guo H; Zheng M; Wu H; Weng Q; He Q; Ding L; Yang B
    Mol Oncol; 2023 Dec; 17(12):2659-2674. PubMed ID: 37606530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment.
    To KKW; Cheung KM; Cho WCS
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7217-7234. PubMed ID: 36905422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma.
    Xie W; Shi L; Quan H; Xiao H; Chen J; Liu J; de Dieu Habimana J; Huang R; Luo J; Chen P; Li Z
    Cell Oncol (Dordr); 2023 Oct; 46(5):1285-1299. PubMed ID: 37099251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer.
    Li Z; Xue H; Li J; Zheng Z; Liu Z; Dong X; Wang H; Chen J; Xu S
    J Exp Clin Cancer Res; 2024 Mar; 43(1):89. PubMed ID: 38520004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone acetylation: a key determinant of acquired cisplatin resistance in cancer.
    Natu A; Verma T; Khade B; Thorat R; Gera P; Dhara S; Gupta S
    Clin Epigenetics; 2024 Jan; 16(1):8. PubMed ID: 38172984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance.
    Yang Z; Wang Y; Liu S; Deng W; Lomeli SH; Moriceau G; Wohlschlegel J; Piva M; Lo RS
    Cancer Discov; 2022 Aug; 12(8):1942-1959. PubMed ID: 35638972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer.
    Liu C; Qian X; Yu C; Xia X; Li J; Li Y; Xie Y; Gao G; Song Y; Zhang M; Xue H; Wang X; Sun H; Liu J; Deng W; Guo X
    Cancer Lett; 2024 Apr; 586():216642. PubMed ID: 38278470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.
    Wang L; Liu X; Han Y; Tsai HI; Dan Z; Yang P; Xu Z; Shu F; He C; Eriksson JE; Zhu H; Chen H; Cheng F
    Cancer Lett; 2024 May; 590():216861. PubMed ID: 38583649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer.
    Wu SM; Jan YJ; Tsai SC; Pan HC; Shen CC; Yang CN; Lee SH; Liu SH; Shen LW; Chiu CS; Arbiser JL; Meng M; Sheu ML
    Cell Biol Toxicol; 2023 Oct; 39(5):1873-1896. PubMed ID: 34973135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
    Harada T; Ohguchi H; Grondin Y; Kikuchi S; Sagawa M; Tai YT; Mazitschek R; Hideshima T; Anderson KC
    Leukemia; 2017 Dec; 31(12):2670-2677. PubMed ID: 28490812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The multiple arrays of a PD1-derived peptide on chromatin specifically bind to PD-L1 and induce doxorubicin resistance in cancer cell lines.
    Zhang X; Liu Z; Guang Y; Jiang B; Park JH
    Biochem Biophys Res Commun; 2024 Feb; 695():149435. PubMed ID: 38154265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy.
    Wen Y; Ye S; Li Z; Zhang X; Liu C; Wu Y; Zheng R; Xu C; Tian J; Shu L; Yan Q; Ai F; Ma J
    Cancer Immunol Immunother; 2024 Jan; 73(1):7. PubMed ID: 38231305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors stabilize the expression of PD-L1 on cell membrane depending on the phosphorylation of GSK3β.
    Gao L; Liu Y; Liu J; Li J; Li H; Liu Y; Meng F; Du X; Gao Y; Li J; Qin FX
    Cancer Med; 2024 May; 13(10):e7083. PubMed ID: 38752436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.
    Pasricha SR; Lim PJ; Duarte TL; Casu C; Oosterhuis D; Mleczko-Sanecka K; Suciu M; Da Silva AR; Al-Hourani K; Arezes J; McHugh K; Gooding S; Frost JN; Wray K; Santos A; Porto G; Repapi E; Gray N; Draper SJ; Ashley N; Soilleux E; Olinga P; Muckenthaler MU; Hughes JR; Rivella S; Milne TA; Armitage AE; Drakesmith H
    Nat Commun; 2017 Sep; 8(1):403. PubMed ID: 28864822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Egr2-independent, Klf1-mediated induction of PD-L1 in CD4
    Teruya S; Okamura T; Komai T; Inoue M; Iwasaki Y; Sumitomo S; Shoda H; Yamamoto K; Fujio K
    Sci Rep; 2018 May; 8(1):7021. PubMed ID: 29728568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylation- and ubiquitination-regulated SFMBT2 acts as a tumor suppressor in clear cell renal cell carcinoma.
    Xie Q; Hu B; Li H
    Biol Direct; 2024 May; 19(1):37. PubMed ID: 38734627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer.
    Wang J; Xu Y; Rao X; Zhang R; Tang J; Zhang D; Jie X; Zhu K; Wang X; Xu Y; Zhang S; Dong X; Zhang T; Yang K; Xu S; Meng R; Wu G
    Clin Transl Med; 2022 Jan; 12(1):e718. PubMed ID: 35083874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy.
    Qin G; Bai F; Hu H; Zhang J; Zhan W; Wu Z; Li J; Fu Y; Deng Y
    Mol Med; 2024 Jan; 30(1):13. PubMed ID: 38243170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.